Wockhardt :td
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Wockhardt's recent strategic shift towards an innovation-led model, particularly with the global launch of its novel antibiotic Zaynich, is expected to significantly impact revenue growth and margins. Management's confidence in a 'hockey stick' growth trajectory, driven by Zaynich's peak revenue potential of $1.5-$2 billion, underscores the company's commitment to addressing unmet medical needs in the antibiotic space. Additionally, the expansion of its biosimilar diabetes franchise, with five products in the pipeline, is anticipated to double business within 24-36 months, further enhancing revenue prospects. Vista's financial outlook reflects a stable balance sheet and improving margins, aligning with these growth initiatives. However, initial costs associated with Zaynich's launch may lead to short-term losses, with breakeven expected within 12-18 months. The broader pharmaceutical industry context, characterized by improving pricing power and a focus on innovative therapies, supports Wockhardt's growth narrative. Over the next 12-24 months, key opportunities include the successful commercialization of Zaynich and the scaling of biosimilars, while watchpoints include potential margin pressures and the execution of operational excellence initiatives
Why We Like This Stock
- The global launch of Zaynich is expected to drive significant revenue growth, with a peak potential of $1.5-$2 billion
- Expansion of the biosimilar diabetes franchise is projected to double business within 24-36 months, enhancing overall revenue
- Management's commitment to operational excellence and AI-driven initiatives supports margin improvement and long-term growth
Things To Watch Out For
- Initial costs associated with the Zaynich launch may result in short-term losses, impacting profitability in the near term
- Potential margin pressures could arise from rising input costs and competitive pricing in key markets
- Execution risks related to operational excellence initiatives may pose challenges to achieving projected growth targets
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,798 | 3,012 | 3,373 | 3,651 | 3,880 |
| Profit Before Tax (Cr.) | -354 | -16 | 323 | 599 | 570 |
| PBT Margin | -12.7% | -0.5% | 957.6% | 16.4% | 14.7% |
| Net Profit (Cr.) | -378 | -23 | 291 | 556 | 504 |
| Earnings Per Share | -22.8 | -0.8 | 18.8 | 32.7 | 31.1 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.